Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T12:01:37.378Z.
Calculation as of: 2026-10-06T12:01:37.378Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f1b6469add1457cabf137e6e5cfb012e486d3d2c84b47330ed8a9effb8bf14c7
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$67.11M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$69.05M
Price/OCF Ratio
N/A
TTM Avg
15.38
3Y Avg
92.53
5Y Avg
55.53
Market Cap
$69.43M
Price/OCF Ratio
0.55
TTM Avg
0.74
3Y Avg
0.74
5Y Avg
0.74
Market Cap
$56.54M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cingulate Inc. (CING) | $63.98M | N/A | N/A | N/A | N/A |
| Alps Group Inc (ALPS)vs › | $66.56M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $67.11M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $60.48M | N/A | 93.25 | 93.25 | 93.25 |
| Champions Oncology, Inc. (CSBR)vs › | $69.05M | N/A | 15.38 | 92.53 | 55.53 |
| Fortress Biotech, Inc. (FBIO)vs › | $69.43M | 0.55 | 0.74 | 0.74 | 0.74 |
| Boundless Bio, Inc. (BOLD)vs › | $58.43M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $56.54M | N/A | N/A | N/A | N/A |
| Gain Therapeutics, Inc. (GANX)vs › | $72.09M | N/A | N/A | N/A | N/A |
| Aldeyra The (ALDX)vs › | $55.72M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
